EC Paediatrics

This study investigates the comparative effectiveness of inhaled Budesonide (BUD) and Fluticasone Propionate (FP) in the management of childhood asthma. Asthma, a chronic inflammatory disease of the airways, is a significant cause of morbidity in children, characterized by episodes of airflow obstruction and hyperresponsiveness. The study aims to compare the peak expiratory flow (PEF), FEV1, FEV1/FVC ratios, response to therapy, and side effects between children treated with Budesonide and Fluticasone Propionate.

Conducted over 18 months at a single tertiary care hospital, this single-center, single-blind, randomized controlled study included 90 newly diagnosed pediatric asthma patients. They were equally divided into two groups: Group A receiving Budesonide and Group B receiving Fluticasone Propionate. The study utilized a 4 block randomization method to ensure equal distribution and blinding of patients to the treatment received.

The results of this study are anticipated to provide valuable insights into the efficacy and safety profiles of Budesonide and Fluticasone Propionate in pediatric asthma management, potentially guiding clinical decision-making and optimizing patient outcomes. The study's findings are particularly relevant given the lack of comparative studies in this area, especially in the Indian context.

 Keywords: Budesonide; Fluticasone Propionate; Children; Asthma

1. Michel O., et al. “Domestic endotoxin exposure and clinical severity of asthma”. Clinical and Experimental Allergy 4 (1991): 441-448.
2. ISAAC Steering Committee. “Worldwide variation in prevalence of symptoms of asthma, allergic rhinoconjunctivitis, and atopic eczema”. Lancet9111 (1998): 1225-1232.
3. Vedanthan PK., et al. “Effect of animal contact and microbial exposures on the prevalence of atopy and asthma in urban vs rural children in India”. Annals of Allergy, Asthma and Immunology 96 (2006): 571-578.
4. Kull I., et al. “Breast-feeding reduces the risk of asthma during the first 4 years of life”. Journal of Allergy and Clinical Immunology 4 (2004): 755-760.
5. Ratageri VH., et al. “Factors associated with severe asthma”. Indian Pediatrics 10 (2000): 1072-1082.
6. Kuo LY., et al. “Effects of budesonide and fluticasone propionate in pediatric asthma patients”. Pediatrics and Neonatology 1 (2010): 31-36.
7. Hoekx JCM., et al. “Fluticasone propionate compared with budesonide: a double-blind trial in asthmatic children using powder devices at a dosage of 400 µgÆday-1”. European Respiratory Journal 11 (1996): 2263-2272.
8. Adams N., et al. “Fluticasone versus beclomethasone or budesonide for chronic asthma in adults and children”. Cochrane Database of Systematic Reviews 4 (2007): CD002310.
9. Price J. “The role of inhaled corticosteroids in children with asthma”. Archives of Disease in Childhood 2 (2000): 10-14.
10. Agertoft L and Pedersen S. “Short-term knemometry and urine cortisol excretion in children treated with fluticasone propionate and budesonide: a dose-response study”. European Respiratory Journal 7 (1997): 1507-1512.
11. Wolthers OD., et al. “Short-term growth during treatment with inhaled fluticasone propionate/formoterol, fluticasone and beclomethasone treatment”. Journal of Aerosol Medicine and Pulmonary Drug Delivery 5 (2017): 373-380.
12. Harrison TW., et al. “Comparison of the systemic effects of fluticasone propionate and budesonide given by dry powder inhaler in healthy and asthmatic subjects”. Thorax 3 (2001): 186-191.
13. Sealed Envelope Ltd. Create a blocked randomisation list (2019).
14. Ferguson AC., et al. “Efficacy and safety of high-dose inhaled steroids in children with asthma: A comparison of fluticasone propionate with budesonide”. The Journal of Pediatrics4 (1998): 422-435.
15. Lim RH., et al. “Risk for asthma in offspring of asthmatic mothers versus fathers: a meta-analysis”. PLoS ONE4 (2010): e10134.
16. Wu Z., et al. “Nebulized step-down budesonide vs. fluticasone in infantile asthma: A retrospective cohort study Corrigendum in /10.3892/etm.2020.9140”. Experimental and Therapeutic Medicine 3 (2020): 1665-1672.
17. van Aalderen WM., et al. “Epidemiology and the concept of underlying mechanisms of nocturnal asthma”. Respiratory Medicine B (1993): 37-39.